- Home
- XFOR vs OBIO Comparison
XFOR vs OBIO Comparison
Compare XFOR & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- OBIO
- Stock Information
- Founded
- XFOR 2014
- OBIO 2017
- Country
- XFOR United States
- OBIO United States
- Employees
- XFOR N/A
- OBIO N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- XFOR Health Care
- OBIO Health Care
- Exchange
- XFOR Nasdaq
- OBIO Nasdaq
- Market Cap
- XFOR 118.4M
- OBIO 118.8M
- IPO Year
- XFOR N/A
- OBIO N/A
- Fundamental
- Price
- XFOR $1.48
- OBIO $2.96
- Analyst Decision
- XFOR Strong Buy
- OBIO Strong Buy
- Analyst Count
- XFOR 3
- OBIO 5
- Target Price
- XFOR $72.33
- OBIO $14.20
- AVG Volume (30 Days)
- XFOR 466.4K
- OBIO 369.8K
- Earning Date
- XFOR 08-07-2025
- OBIO 08-11-2025
- Dividend Yield
- XFOR N/A
- OBIO N/A
- EPS Growth
- XFOR N/A
- OBIO N/A
- EPS
- XFOR 2.16
- OBIO N/A
- Revenue
- XFOR $31,364,000.00
- OBIO $2,886,000.00
- Revenue This Year
- XFOR $1,106.53
- OBIO $20.47
- Revenue Next Year
- XFOR N/A
- OBIO $11.45
- P/E Ratio
- XFOR $0.66
- OBIO N/A
- Revenue Growth
- XFOR N/A
- OBIO 30.23
- 52 Week Low
- XFOR $1.41
- OBIO $2.37
- 52 Week High
- XFOR $26.96
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- XFOR 25.85
- OBIO 51.30
- Support Level
- XFOR $1.81
- OBIO $2.78
- Resistance Level
- XFOR $2.12
- OBIO $2.94
- Average True Range (ATR)
- XFOR 0.21
- OBIO 0.21
- MACD
- XFOR -0.01
- OBIO -0.00
- Stochastic Oscillator
- XFOR 1.88
- OBIO 60.87
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.